Twice-a-year R500k HIV prevention shot wins US approval
Gilead Sciences said it won US approval for a drug to prevent HIV that only has to be given twice a year, making it a convenient new way to ward off infection in a wide range of people.
In two big international studies published last year, the medicine demonstrated a powerful ability to avert HIV infection. With no vaccine on the horizon, the ultra-long acting shot has been hailed by activists as perhaps the best tool the world has so far to wipe out the virus.
The medicine will be marketed as Yeztugo, Gilead said, and will have a list price of $28 218 (R509 000) per year. That compares to a list price of about $26 400 per year for Descovy, the company's daily pill for HIV prevention.
Shares of Gilead briefly jumped as much as 3.5%, their biggest gain in almost a month. The stock had risen 17% this year through Tuesday, outperforming a 2% increase in the S&P 500 index.
Even as it works to make the drug a bestseller in rich countries like the US, the Foster City, California-based company will face great pressure to rapidly roll it out for poor and middle income countries that have been hit hard by HIV.
'This is a milestone moment in the decades-long fight against HIV,' Gilead Chief Executive Officer Daniel O'Day said in an emailed statement. 'We now have a way to end the HIV epidemic.'
The approval and rollout of the drug will being closely watched by Wall Street, which is hoping it will provide a new source of growth to turbocharge Gilead's mature portfolio of pills for HIV and hepatitis C. It's expected to surpass $4 billion in annual sales by 2031, according to analysts surveyed by Bloomberg.
It will compete with Apretude, a prevention shot from ViiV Healthcare, majority-owned by GSK Plc, that's given every other month.
While the incidence of HIV has declined since its peak in the 1990s, some 1.3 million people are infected with the virus each year. Some of the highest rates of new cases occur in various countries in Africa. And while daily prevention pills work, they have downsides. People can forget to take them. Others may not want to get them because of the stigma surrounding HIV, or because they worry the pill bottle may inadvertently divulge their high-risk status.
Gilead has filed for approval in numerous places, including South Africa, Brazil, Australia, Canada, the European Union, and the EU Medicines For All programme, which helps speed the review of drugs that will be used in developing countries.
In one large international trial published last November in men and transgender people, the drug prevented all but two HIV cases among 2 180 people given it, a rate 96% lower than the background incidence level in that population. It was also superior to the company's old HIV prevention pill Truvada.
And in June, Gilead said a trial of the shot in women and adolescent girls in Africa prevented 100% of HIV cases, a result the company said was unprecedented.
Side effects include injection site reactions, which caused 1.2% of people in one study to stop taking it. Gilead already sells the same drug, lenacapavir, as a treatment for people with multidrug-resistant HIV under the brand Sunlenca.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
an hour ago
- New York Times
‘Little Lobbyists' Urge Senators to Oppose Trump's Bill Cutting Medicaid
Landry Bell, a 1-year-old boy who was born with Down syndrome, wriggled and smiled in his big sister's lap on the floor outside Republican Senator Mike Lee's office this week as he took a break from going office to office with his mother while she explained how cuts to Medicaid would devastate their family. Wearing a bright blue T-shirt emblazoned with the words 'Little Lobbyists,' Landry was among a group of children with serious medical needs who crisscrossed the Capitol with their parents urging senators to vote 'no' on the sprawling Republican bill carrying President Trump's agenda. The legislation would cut deeply into Medicaid to help pay for large tax cuts that would benefit businesses and the richest Americans. The Senate version of the legislation would make even more aggressive cuts to Medicaid than the version of the legislation that passed the House last month. Those proposed reductions, and the elimination of some clean-energy tax credits, are among the most contentious provisions driving debate on the bill among Republicans, as party leaders push to complete it and send it to Mr. Trump's desk within weeks. The Little Lobbyists formed in 2017 during Mr. Trump's first term to push back against Republican efforts to repeal the Affordable Care Act, taking to Capitol Hill to demand that lawmakers oppose the move. Their successful campaign to save the law was part of a broader backlash against the proposal, which was driven in large part by major health care lobbies, like hospitals and insurance companies, as well as patient groups worried about losing insurance coverage. Want all of The Times? Subscribe.
Forbes
an hour ago
- Forbes
The Unsung and (Often Exhausted) Heroes: Moms
The young mother was visibly exhausted. She had been up for two nights as her six-month-old ran a fever and cried nonstop. She had thought about going to the ER but worried about the long wait, especially without childcare for her two-year-old as her husband was out of town. Now she was in the pediatrics office with an air of despair. 'Please help me. I don't know what's wrong with my child". Parenting Can Be Stressful Being a parent is a journey, even in the best of times. Whether it's a sick infant, a clumsy toddler with a broken arm, a 9-year old starting the soccer season with a concussion, or a teen struggling with anxiety at school, the potential challenges can be endless. Unfortunately, the weight of parenting and supporting kids through this myriad of issues often falls disproportionately on moms. Almost 25% of women leave their jobs in the first year after having kids. After five years, only about 30 percent of these moms have returned to work. Over three-quarters of moms report they are the ones responsible for managing their children's healthcare. It is not surprising to see that JAMA recently published a study about the stress and decline in mental health that moms are experiencing. This seems to be relevant to many professions. In a Healio survey of physicians, 64 percent of women reported that they had caregiving responsibilities, and greater than 50% reported that this had a significant impact on their stress levels. Mental Health is Often Impacted Maternal stress and mental health can have rippling effects and impact kids' own mental health, affect their social skills, educational success, and even their weight. These consequences may begin even before birth – infants of mothers dealing with depression, anxiety, or stress while they were pregnant have been shown to struggle more with social and emotional development. Parental mental illness is one of the adverse childhood experiences that the American Academy of Pediatrics flags as high risk for leading to poor health as adults. Community is Key Stress and mental illness do not exist in a vacuum - a multitude of external factors exert stress on a parent's day-to-day life, from financial instability and food insecurity, to lack of childcare and mental health services. Policies that protect and expand social services for families would help to alleviate many stressors that parents may face, including protections for SNAP, Medicaid, and legislation to support affordable childcare. Guaranteed robust and paid maternity leave policies would allow new moms to heal, rest, and adapt to this next chapter. In Europe, for example, many countries offer up to a year of parental leave, with much of it paid. Online community support can be helpful and some resources do exist. The National Maternal Mental Health Hotline is available at 1-833-TLC-MAMA (1-833-852-6262) via text or call as a 24/7 service for pregnant people or moms to talk to counselors who can provide support and refer them to local resources. Self Compassion Can Buffer Stress But an essential change to help our moms, often the 'Chief Health Officers' of the family, is a culture shift. Moms and caregivers should be encouraged to get off the treadmill, pause, take care of themselves and support systems should be in place to allow this to happen. This concept of 'self compassion' has been studied extensively and has made a difference in teachers, healthcare professionals and parents. The 'reset' includes breathing techniques, visualization, guided meditation and mindset shifts. To allow for these pauses, our essential caregivers must also have an inner team of family and friends that they can hand off to, or lean on, so they can take time to reset and breathe. Imagine this - the young mother calls her neighbor, who watches her toddler while she takes her baby to urgent care. The doctor diagnoses the child with an ear infection, prescribes antibiotics and shows her how to suction her baby's nose so he (and she) can sleep soundly. Everyone wakes up the next day rested and calm. Self compassion, connection and a village are essential parts of helping our most significant caregivers- moms. When we uplift our moms and other caregivers, there is a rippling effect to the health of the children now and longterm. Written with Alice Gao, MD.
Forbes
an hour ago
- Forbes
A New Study Targets Genetic Risk For Mental Illness
For centuries, the genetic lottery has shaped our health and our futures. In Destiny's Child No Longer: Rewriting Genetic Fate, the story is told of how science is beginning to tip the scales, offering hope to individuals once bound by the DNA they inherited. Nowhere is this more apparent than in the effort to address rare genetic conditions that dramatically raise the risk of serious mental health challenges, including schizophrenia. Some children are born missing a vital stretch of their DNA. This genetic change is known as a microdeletion. Although small, this missing segment can have far-reaching effects on development, influencing everything from the heart and immune system to facial shape and the ability to speak clearly. The range of physical symptoms is broad: some children may be born with heart defects, others with weakened immune defenses that make them more susceptible to infections, and still others with differences in facial features or palate formation that can affect feeding and speech. As these children grow and develop, they often face significant challenges in their brains. Many experience difficulties with learning, memory, and attention. Social interactions can be especially challenging, as some individuals struggle to recognize and interpret emotions and maintain healthy relationships. Emotional regulation may also be affected, leading to increased anxiety and mood swings. These issues can persist into adulthood, impacting overall quality of life. Perhaps most concerning is the sharply increased risk of severe psychiatric disorders. Among these, schizophrenia, a complex mental health condition marked by hallucinations, delusions, and disorganized thinking, stands out. While schizophrenia is influenced by a combination of many genes and environmental factors, research consistently shows that genetic factors account for up to 80% of the risk. In the general population, the lifetime risk of developing schizophrenia is about 1%. However, for those with rare genetic deletions, the risk can be higher. It's believed that the loss of specific genes in these tiny DNA segments disrupts brain development and connectivity, making the brain more vulnerable to the onset of psychiatric illness later in life. Importantly, not everyone with such a deletion will develop schizophrenia or other psychiatric conditions. Knowing this highlights the interplay between genetic vulnerability and environmental influences that together shape mental health outcomes. Still, the presence of a genetic deletion dramatically tips the odds, making early identification and intervention critical for affected families. Until recently, there were no treatments that addressed the root cause of these cognitive and psychiatric symptoms. Care focused on managing day-to-day challenges, but the underlying biology remained untouched. That is why a new study published in eLife is noteworthy. It focused on the molecular consequences of this DNA deletion, specifically examining how it disrupts the brain's normal development and function. The study found that the deletion disrupts the brain's natural gene regulators. This results in the overproduction of a protein, which, when present in excess, disrupts the growth and communication of brain cells. This overproduction contributes to the symptoms observed in individuals affected by the condition. The breakthrough occurred via a gene-targeting therapy that used short pieces of synthetic genetic material designed to silence specific genes. By delivering these molecules to the brains of adult mice with the genetic deletion, they were able to reduce protein levels. The result: memory and learning improved, and the benefits lasted for more than two months after a single treatment. This research marks a significant step forward for several reasons. First, it demonstrates that the effects of a genetic brain disorder are not necessarily permanent. Intervening at the molecular level can restore function, at least in animal models. Second, the technology used here is already being used to treat other neurological diseases. This raises hopes that similar approaches could be adapted for people. Finally, the study sheds light on the broader mechanisms that link rare genetic changes to common mental illnesses like schizophrenia, offering new clues for future therapies. For families living with the daily realities of this genetic condition, the promise of a therapy that targets the underlying cause rather than just the symptoms could be life-changing. Imagine a young adult who has struggled for years with memory lapses and social difficulties is now able to participate more fully in school, work, and relationships. While much work remains to be done before such treatments become widely available, the path is more straightforward than ever before. As we stand at the threshold of a new era in genetic medicine, stories like this remind us that destiny, once written in our genes, is now open to revision. With each advance, the possibility grows that inherited risk does not have to mean inherited fate. The challenge ahead is to ensure that these breakthroughs are translated into real-world therapies, so that the promise of rewriting genetic destiny becomes a reality for all who need it.
